Author Response:
Evaluation Summary:
This manuscript is of primary interest to readers in the field of infectious diseases especially the ones involved in COVID-19 research. The identification of immunological signatures caused by SARS-CoV-2 in HIV-infected individuals is important not only to better predict disease outcomes but also to predict vaccine efficacy and to potentially identify sources of viral variants. In here, the authors leverage a combination of clinical parameters, limited virologic information and extensive flow cytometry data to reach descriptive conclusions.
We have extensively reworked the paper.
Reviewer #1 (Public Review):
The methods appear sound. The introduction of vaccines for COVID-19 and the emergence of variants in South Africa and how they may impact PLWH is well discussed making the findings presented a good reference backdrop for future assessment. Good literature review is also presented. Specific suggestions for improving the manuscript have been identified and conveyed to the authors.
We thank the Reviewer for the support.
Reviewer #2 (Public Review):
Karima, Gazy, Cele, Zungu, Krause et al. described the impact of HIV status on the immune cell dynamics in response to SARS-CoV-2 infection. To do so, during the peak of the KwaZulu-Natal pandemic, in July 2020, they enrolled a robust observational longitudinal cohort of 124 participants all positive for SARS-CoV-2. Of the participants, a group of 55 people (44%) were HIV-infected individuals. No difference is COVID-19 high risk comorbidities of clinical manifestations were observed in people living with HIV (PLWH) versus HIV-uninfected individuals exception made for joint ache which was more present in HIV-uninfected individuals. In this study, the authors leverage and combine extensive clinical information, virologic data and immune cells quantification by flow cytometry to show changes in T cells such as post-SARS-CoV-2 infection expansion of CD8 T cells and reduced expression CXCR3 on T cells in specific post-SARS-CoV-2 infection time points. The authors also conclude that the HIV status attenuates the expansion of antibody secreting cells. The correlative analyses in this study show that low CXCR3 expression on CD8 and CD4 T cells correlates with Covid-19 disease severity, especially in PLWH. The authors did not observe differences in SARS-CoV-2 shedding time frame in the two groups excluding that HIV serostatus plays a role in the emergency of SARS-CoV-2 variants. However, the authors clarify that their PLWH group consisted of mostly ART suppressed participants whose CD4 counts were reasonably high. The study presents the following strengths and limitations
We thank the Reviewer for the comments. The cohort now includes participants with low CD4.
Strengths:
A. A robust longitudinal observational cohort of 124 study participants, 55 of whom were people living with HIV. This cohort was enrolled in KwaZulu-Natal,South Africa during the peak of the pandemic. The participants were followed for up to 5 follow up visits and around 50% of the participants have completed the study.
We thank the Reviewer for the support. The cohort has now been expanded to 236 participants.
B. A broad characterization of blood circulating cell subsets by flow cytometry able to identify and characterize T cells, B cells and innate cells.
We thank the Reviewer for the support.
Weaknesses:
The study design does not include
A. a robust group of HIV-infected individuals with low CD4 counts, as also stated by the authors
This has changed in the resubmission because we included participants from the second, beta variant
dominated infection wave. For this infection wave we obtained what we think is an important result,
presented in a new Figure 2:
![source: imgur.com](https://i.imgur.com/lZMdI32.png)
This figure shows that in infection wave 2 (beta variant), CD4 counts for PLWH dropped to below the
CD4=200 level, yet recovered after SARS-CoV-2 clearance. Therefore, the participants we added had
low CD4 counts, but this was SARS-CoV-2 dependent.
B. a group of HIV-uninfected individuals and PLWH with severe COVID-19. As stated in the manuscript the majority of our participants did not progress beyond outcome 4 of the WHO ordinal scale. This is also reflected in the age average of the participants. Limiting the number of participants characterized by severe COVID-19 limits the study to an observational correlative study
Death has now been added to Table 1 under the “Disease severity” subheading. The number of
participants who have died, at 13, is relatively small. We did not limit the study to non-critical cases.
Our main measure of severity is supplemental oxygen.
This is stated in the Results, line 106-108:
“Our cohort design did not specifically enroll critical SARS-CoV-2 cases. The requirement for
supplemental oxygen, as opposed to death, was therefore our primary measure for disease severity.”
This is justified in the Discussion, lines 219-225:
“Our cohort may not be a typical 'hospitalized cohort' as the majority of participants did not require supplemental oxygen. We therefore cannot discern effects of HIV on critical SARS-CoV-2 cases since these numbers are too small in the cohort. However, focusing on lower disease severity enabled us to capture a broader range of outcomes which predominantly ranged from asymptomatic to supplemental oxygen, the latter being our main measure of more severe disease. Understanding this part of the disease spectrum is likely important, since it may indicate underlying changes in the immune response which could potentially affect long-term quality of life and response to vaccines.”
C. a control group enrolled at the same time of the study of HIV-uninfected and infected individuals.
This was not possible given constraints imposed on bringing non-SARS-CoV-2 infected participants into a hospital during a pandemic for research purposes. However, given that the study was longitudinal, we did track participants after convalescence. This gave us an approximation of participant baseline in the absence of SARS-CoV-2, for the same participants. Results are presented in Figure 2 above.
D. results that elucidate the mechanisms and functions of immune cells subsets in the contest of COVID-19.
We do not have functional assays.
Reviewer #3 (Public Review):
Karim et al have assembled a large cohort of PLWH with acute COVID-19 and well-matched controls. The main finding is that, despite similar clinical and viral (e.g., shedding) outcomes, the immune response to COVID-19 in PLWH differs from the immune response to COVID-19 in HIV uninfected individuals. More specifically, they find that viral loads are comparable between the groups at the time of diagnosis, and that the time to viral clearance (by PCR) is also similar between the two groups. They find that PLWH have higher proportions and also higher absolute number of CD8 cells in the 2-3 weeks after initial infection.
The authors do a wonderful job of clinically characterizing the research participants. I was most impressed by the attention to detail with respect to timing of viral diagnosis as it related to symptom onset and specimen collection. I was also impressed by the number of longitudinal samples included in this study.
We thank the Reviewer for the support.